<code id='6022DA83F7'></code><style id='6022DA83F7'></style>
    • <acronym id='6022DA83F7'></acronym>
      <center id='6022DA83F7'><center id='6022DA83F7'><tfoot id='6022DA83F7'></tfoot></center><abbr id='6022DA83F7'><dir id='6022DA83F7'><tfoot id='6022DA83F7'></tfoot><noframes id='6022DA83F7'>

    • <optgroup id='6022DA83F7'><strike id='6022DA83F7'><sup id='6022DA83F7'></sup></strike><code id='6022DA83F7'></code></optgroup>
        1. <b id='6022DA83F7'><label id='6022DA83F7'><select id='6022DA83F7'><dt id='6022DA83F7'><span id='6022DA83F7'></span></dt></select></label></b><u id='6022DA83F7'></u>
          <i id='6022DA83F7'><strike id='6022DA83F7'><tt id='6022DA83F7'><pre id='6022DA83F7'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:866
          Cambridge: AbbVie
          Ruby Wallau for STAT

          AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

          Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

          advertisement

          Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          Researchers separate signal from noise in heart wearable data
          Researchers separate signal from noise in heart wearable data

          AdobeAswearablehealthdevicesgrowmorepopularintheU.S.,there’sagrowingopportunitytotrackthebroaderadul

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          The U.S. needs a new definition of substance use “recovery”

          Adobe“WhenIuseaword,”oneof19thcenturyBritishauthorandmathematicianLewisCarroll’scharactersoncesaid,“